Wiki
Short explainers. Every page lists its sources.
Basics
- What NAMs are
Definitions, the main method families, and why 2025 to 2026 changed the trajectory.
Regulation
- US regulation and policy
Congress, FDA, NIH and EPA: what is final, what is draft, and what is pending.
- EU, UK and international
The EU chemicals roadmap, EMA and EFSA moves, the UK strategy's dated targets, and other regulators.
- How NAMs get accepted
Validation versus qualification, context of use, and why the first qualified organ-chip matters.
Technologies
- Organ-on-chip and MPS
What the technology does, where the evidence is strongest, and who sells it.
- Organoids and 3D models
Spheroids, stem cell organoids and immune organoids, and how ready they are for screening and safety.
- Engineered tissue, cells and ex vivo organs
Reconstructed and foundry-grown tissues, iPSC and primary cells, and perfused donor organs.
- In silico: biosimulation, QSAR and AI
PBPK and QSP, cheminformatics and expert systems, and the new wave of AI toxicity and ADMET models.
Market
- Buyers, channels and consolidation
Who pays for NAMs today, how they buy, and what recent deals show.
- Market size: what is knowable
Why published market estimates disagree, and which numbers are more reliable.
About
- Methodology
Scope, sources, confidence tags, update cadence and corrections.